[메디칼업저버 박선재 기자] The annual academic conference of the American Society of Clinical Oncology (ASCO 2023), which discusses new cancer treatments and treatments, will be held in Chicago from June 2 to 6.
Around 7,000 abstracts presented by researchers from all over the world were received at this conference, which is an increase of 6-7% compared to other years.
The theme of this year’s conference is ‘Patient Centered Therapy’. The organizers of the academic conference seem to focus exclusively on this area, with 200 sessions allocated.
First of all, Dr. Yvonne Bombard from the University of Toronto, Canada, presents a communication approach for oncologists that is sensitive to patient needs.
In addition, there are sessions to discuss how to establish a relationship where oncologists and patients treat each other while maintaining trust, as well as discussion sessions on ethical obligations as oncologists.
More research papers than any other year
The core of ASCO, of course, is the presentation of a plethora of research papers. This year, it is expected to be a field of competition for newly published research results by field.
In the field of lung cancer, a research team led by Professor Bjorn H. Henning Gronberg from the Norwegian University of Science and Technology presented clinical phase 2 survival data comparing high-dose and standard-dose thoracic radiation therapy (TRT) for patients with lung cancer. limited-stage small cell lung (LS-SCLC)’ is revealed.
Research involving CheckMate, a regular customer of ASCO, also appears on stage.
A research team led by Professor Jonathan Spicer from McGill University in Canada published the CheckMate 816 study comparing Opdivo (ingredient: nivolumab) + chemotherapy with chemotherapy alone as pre-operative adjuvant therapy for patients with resectable non-small cell lung cancer and followed for 3 years.
Research on patients with genetic mutations is also attracting attention.
The results of the Sunvozertinib study conducted by a Chinese research team on non-small cell lung cancer patients with EGFR exon 20 insertion mutations are awaiting an audience.
In addition, a single-group, phase 2 clinical trial, WJOG14821L, in which Lumagras (Sotolasib) + carboplatin + pemetrexed is administered in patients with advanced non-squamous non-small cell lung cancer with a KRAS G12C mutation, is also receiving preparing it for launch..
A Japanese research team will also present the NEJ057 clinical study comparing first-line immunosuppressive monotherapy with chemotherapy and combination therapy for elderly patients with advanced non-small cell lung cancer.
A research team from the MD Anderson Cancer Center in the US is also joining.
The research team is also awaiting a clinical trial comparing Libtayo (semiplimab) and chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) with high PD-L1 expression (50% or more) and DNA circulating tumor (ctDNA). There are.
A new combination of gastrointestinal cancer therapies
Research that stands out in the field of gastric cancer is also attracting attention. It is a ‘CodeBreaK 101’ study conducted with a new combination by Professor David S. Hong’s research team at the MD Anderson Cancer Center in the United States.
The research team conducted Lumacras (Sotorasib) + Vectibix (panitumumab) and FOLFIRI combination therapy for patients with KRAS G12C mutation metastatic colorectal cancer (mCRC) with a history of treatment. This study is a result of the safety and efficacy evaluation in phase 1b.
A phase 3 clinical trial of ‘NAPOLI 3’ by Professor Eileen Mary O’Reilly’s research team at the Memorial Sloan-Kettering Cancer Center in the United States is also drawing attention.
The research team will reveal the results comparing the NALIRIFOX (irinotecan + 5-FU/leucovorin + oxaliplatin) administration group and the gemcitabine + Abraxane administration group for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) without a history of treatment.
In addition, 12-18 month survival data from NAPOLI 3 clinical phase 3 await investigators.
Research results for relatlimab, an immuno-oncology drug, are also revealed
In the field of hematologic tumor cancer and immunotherapy, various papers are about to begin.
In particular, the results of the COMMANDS phase 3 clinical trial conducted by MD Anderson of Professor Guillermo Garcia-Manero’s research team are attracting attention.
This study was conducted in transfusion-dependent (TD) patients with low-risk myelodysplasia syndrome (LR-MDS) not using erythropoiesis-stimulating agents (ESA) with Reblozil (Ruspartercept) and epoetin alfa, a study comparing
A 4-year follow-up study of the CAPTIVATE study is also preparing to start.
In this study, Imbruvica (ibrutinib) + Venclexta (venetoclax) was studied in a fixed duration (FD) cohort of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) administered as the first study.
In addition, the RELATIVITY-047 study (Abstract 9502), which studied relatlimab, an immuno-oncology drug being developed by BMS, is also pending publication.
Relatlimab targets the LAG-3 biomarker. In this study, the overall survival (OS) and objective response rate (ORR) results of the phase 2/3 clinical trial of Opdivo + Relatlimab combination therapy in advanced melanoma are published.
